Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01663363 | Safety and Effectiveness of Wavefront-Guided LASIK Corrections of Myopic Refractive Errors | PHASE3 | COMPLETED | 170 | — | — | Aug 1, 2012 | Jul 1, 2015 | Feb 4, 2025 | - | — |
| Arm | Type | Description |
|---|---|---|
| wavefront-guided LASIK | EXPERIMENTAL | LASIK correction of myopic refractive errors. Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System. |
| Name | Type | Description |
|---|---|---|
| LASIK correction of myopic refractive errors | DEVICE | Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System |
Inclusion Criteria: * 18 years of age or greater * Best Spectacle Corrected Visual Acuity (BSCVA) of 20/20 or better * Uncorrected visual acuity (UCVA) of 20/40 or worse * Less than 0.75D difference between cycloplegic and manifest refraction sphere. * Demonstration of refractive stability * Antici...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Cooper Companies, Inc. | COO | 3 | NA | Undisclosed |
| Bausch + Lomb Corporation | BLCO | 4 | NA | Undisclosed |
| Johnson & Johnson | JNJ | 1 | NA | Undisclosed |
| Alcon AG | ALC | 2 | NA | Undisclosed |